Eli Lilly and Company Earnings Call Transcripts
Fiscal Year 2026
-
Orforglipron is set for U.S. launch in early Q2 with rapid distribution and broadening access, including Medicare coverage by July. The company is expanding its obesity and diabetes portfolio, investing in global markets, and leveraging AI for operational gains, while also advancing non-incretin assets in oncology and neuroscience.
-
The conference highlighted robust momentum in obesity and diabetes, with major pipeline advances, global expansion, and direct-to-consumer growth. Key access wins in Medicare and Medicaid, innovative partnerships, and a strong competitive stance set the stage for continued growth.
Fiscal Year 2025
-
Delivered 45% revenue growth in 2025, driven by key product launches and strong international expansion. 2026 guidance targets $80–$83 billion revenue, with continued volume growth offsetting price erosion. Robust R&D pipeline and major investments in manufacturing and AI support future growth.
-
Leadership highlighted expansion in obesity treatments, digital access via LillyDirect, and payer partnerships. Medicare and Medicaid access for obesity drugs will expand in 2026–2027, with new launches and pricing models. Pipeline innovation spans cardiometabolic, neuro, and immunology.
-
Q3 2025 saw 54% revenue growth, strong global uptake of key products, and raised full-year guidance. Major pipeline milestones and manufacturing expansions support future growth, while pricing and access dynamics remain key watchpoints.
-
Revenue and product growth remain strong, with key products driving industry-leading performance and manufacturing capacity expanding globally. Orforglipron is set for a major launch, supported by robust R&D, disciplined investment, and a value-based pricing strategy. Long-term growth is underpinned by innovation, risk-taking in new therapeutic areas, and strategic disruption initiatives.
-
The oncology strategy targets common cancer vulnerabilities and treatment resistance, with several phase III trials and new launches progressing. Incretin portfolio highlights include strong efficacy and safety for oral GLP-1 and tirzepatide, with broad development in obesity and diabetes. Jaypirca's positive CLL data and a diversified metabolic pipeline support future growth.
-
Strong Q2 results were driven by key product launches and robust international uptake, with Orforglipron positioned for global growth in both diabetes and weight management. Guidance for 2025 reflects improved supply certainty, ongoing reimbursement efforts, and continued investment in a diverse pipeline.
-
Q2 2025 saw 38% revenue growth, strong sales from Mounjaro and Zepbound, and positive Phase III data for orforglipron and tirzepatide. Guidance for full-year revenue and EPS was raised, with continued investment in R&D and manufacturing capacity. CVS formulary changes and policy reforms present headwinds.
-
Significant progress was highlighted in expanding the cardiometabolic pipeline, with orforglipron and retatrutide advancing toward global launches and multiple phase 3 readouts expected. Orforglipron demonstrated strong efficacy and safety, and the company is preparing for broad market access and segmentation.
-
US policy discussions focus on patient affordability and direct-to-consumer models, with pricing strategies and payer dynamics remaining stable. International launches are progressing rapidly, and multiple data readouts are expected for key assets. Margin expansion and disciplined investment continue to support growth.
-
Executives discussed ongoing policy engagement, major manufacturing investments, and disciplined pricing strategies in obesity and diabetes. International expansion and new product launches, especially orforglipron, are expected to drive significant future growth.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all director nominees and management proposals (except for Articles of Incorporation amendments) passing. Strong financial growth, major R&D and manufacturing investments, and new product launches were highlighted.
-
Q1 2025 saw 45% revenue growth, strong performance from key products, and robust pipeline progress, including positive Orforglipron data. Guidance was reaffirmed despite pricing pressures and PBM changes, with significant U.S. manufacturing investments and expanding global reach.
-
Revenue is projected to grow 32% this year, driven by incretin portfolio expansion, new product launches, and global market rollouts. Major manufacturing investments and a robust pipeline, including orfoglipron, support long-term growth. Gross margin is expected to remain stable at 82–83%.
-
Key late-stage readouts are expected for Orforglipron, Retatrutide, and Jaypirca, with Orforglipron positioned for both efficacy and safety similar to semaglutide. Oncology efforts focus on label expansion for Jaypirca and differentiated breast cancer assets, while future growth may be driven by Alzheimer's prevention and Lp(a) therapies.
-
2024 saw exceptional growth driven by incretin products and portfolio expansion, with 2025 guidance targeting another 32% increase. Capacity and access are set to improve, while the pipeline remains robust with key data readouts ahead.
Fiscal Year 2024
-
Q4 2024 revenue surged 45% year-over-year, led by Mounjaro and Zepbound, with strong new product launches and global expansion. 2025 guidance projects ~32% revenue growth, continued margin expansion, and robust R&D investment, while access and supply for key products remain priorities.
-
Q3 2024 saw 42% revenue growth, led by Mounjaro and Zepbound, with strong U.S. and international demand. Manufacturing expansion, new product launches, and pipeline progress support an updated 2024 revenue guidance of $45.4B–$46B and EPS of $12.05–$12.55.
-
Major oncology pipeline overhaul led to a diversified, modern portfolio with multiple new clinical starts in 2024. Verzenio maintains strong market share, and the positive EMBER-3 trial for Imlunestrant marks a key milestone. Zepbound vial launch in the U.S. aims to meet demand and address counterfeit risks.
-
Q2 2024 saw 36% revenue growth, driven by Mounjaro, Zepbound, and Verzenio, with strong U.S. and international performance. Full-year revenue guidance was raised by $3 billion, and key pipeline milestones were achieved, including FDA approval of Kisunla and positive tirzepatide trial results.
-
Key priorities include expanding manufacturing, accelerating launches of diabetes and obesity drugs, and advancing a robust pipeline with late-stage assets like orforglipron and retatrutide. Market access is improving, with pricing expected to decline as coverage broadens.
-
The oncology unit has overhauled its strategy, ending most legacy projects and focusing on a diversified, biology-driven pipeline. Key brands Verzenio and Jaypirca perform strongly. New clinical programs, including radioligand therapies, are advancing, with efforts to broaden trial access and maximize patient impact.<document-